Extracorporeal magnetic innervation therapy for stress urinary incontinence.
N T Galloway, R E El-Galley, P K Sand...
https://pubmed.ncbi.nlm.nih.gov/10367836/Actively Recruiting
Led by Corewell Health East · Updated on 2026-07-09
110
Participants Needed
1
Research Sites
8 weeks
Total Duration
Stress urinary incontinence SUI is a condition causing involuntary urine leakage during activities that increase abdominal pressure, such as coughing or laughing. It affects both men and women and can impact quality of life by limiting daily activities. This trial evaluates the effectiveness of the Emsella chair, which uses electromagnetic technology, compared to a sham treatment to treat SUI. Participants are randomly assigned to either the active treatment group using the Emsella chair or the sham group. The active treatment delivers high-intensity focused electromagnetic stimulation to the pelvic floor muscles, simulating the effect of 11,200 Kegel exercises in 28 minutes. Treatment consists of eight sessions over four weeks, with two sessions per week. The sham group receives a similar procedure with minimal electromagnetic power below therapeutic levels. During the study, participants will undergo assessments of SUI symptoms and quality of life at baseline and after treatment completion. Questionnaires measuring urinary incontinence episodes, symptom severity, urogenital distress, sexual function, and quality of life are collected up to eight weeks after treatment. Safety and tolerability of the device are also monitored. The total study duration includes the 4-week treatment period and follow-up evaluations up to 8 weeks post-treatment.
CONDITIONS
BTL Emsella Chair Versus Sham for the Treatment of Stress Urinary Incontinence
K
Katherine Kim, RN
J
Jennifer Giordano, RN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Corewell Health East
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | BTL Emsella Chair | Sham Emsella Chair | Supervised PFMT (Current Standard) |
|---|---|---|---|
| What it is | A chair‑based device delivering high‑intensity focused electromagnetic stimulation (HIFEM) to induce pelvic floor muscle contractions. | A sham version providing minimal sensation below therapeutic level (<10% power). | Supervised pelvic floor muscle training (PFMT) with trained professionals for at least 3 months. |
| Role in the trial | Investigational active treatment arm. | Randomized placebo‑control (sham) arm to measure device effect. | Not part of the trial; represents standard non‑device therapy outside the study. |
| Primary use | Test the efficacy of HIFEM chair for reducing stress urinary incontinence. | Control comparison to evaluate active intervention's effect. | Widely used non‑invasive first‑line therapy for managing SUI. |
| How it is performed | Participants sit fully clothed on the chair while HIFEM pulses induce pelvic floor muscle contraction over treatment phases. | Participants sit similarly but receive sub‑therapeutic sham stimulation (<10% power) to mimic procedure. | Series of guided pelvic floor muscle exercises taught and supervised by trained healthcare professionals. |
| Evidence status | Early efficacy data exist but no published sham‑controlled trials for the commercial Emsella device; independent studies limited. | Sham arm included only within this single trial; no broader evidence relevance. | Strong evidence supports PFMT as effective first‑line treatment, resulting in symptom improvement in many patients. |
| Important risks | Safety data limited; no significant adverse effects reported in similar magnetic stimulation studies. | Sham stimulation poses minimal risk, mainly involving device exposure without therapeutic energy. | PFMT is non‑invasive and generally safe with no device‑related risks. |
| Important limitations | Lacks sham‑controlled data for the marketed device; long‑term outcomes and comparison to PFMT unknown. | Sham control is internal to this trial; broader interpretability depends on trial execution. | Effectiveness depends on proper technique and adherence over time; standardized protocols are variable. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 weeks
Participants receive eight sessions of either active electromagnetic stimulation using the Emsella chair or a sham treatment over four weeks.
Two treatments per week for 4 weeks
Duration - 8 weeks
Participants complete assessments to measure changes in urinary incontinence symptoms, quality of life, and safety up to 8 weeks after treatment ends.
Periodic assessments during follow-up
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
N T Galloway, R E El-Galley, P K Sand...
https://pubmed.ncbi.nlm.nih.gov/10367836/Corewell Health East
Lead Sponsor